Leuphasyl vs Palmitoyl Tetrapeptide-7
A side-by-side research comparison of Leuphasyl and Palmitoyl Tetrapeptide-7 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Leuphasyl | Palmitoyl Tetrapeptide-7 |
|---|---|---|
| Full name | Leuphasyl (Pentapeptide-18) | Palmitoyl Tetrapeptide-7 (Pal-GQPR) |
| Category | Skin & Anti-Aging | Skin & Anti-Aging |
| Status | Research compound | Research compound |
| Mechanism | Binds enkephalin receptors on neuronal membranes, reducing calcium influx and neurotransmitter release at the presynaptic level. Works upstream of argireline. | Inhibits IL-6 release from keratinocytes and reduces inflammation-mediated MMP activation, preserving existing collagen while complementing Pal-GHK collagen building. |
| Molecular weight | 599.7 Da | 693 Da |
| Half-life | 6-10 hours (topical) | 8-12 hours (topical) |
| Bioavailability | Moderate (topical) | Good (topical) |
| Typical dose | 3-5% solution | 2-4% in formulation |
| Frequency | 2x daily | 1-2x daily |
| Route | Topical | Topical |
Leuphasyl reported benefits
- Complements argireline action
- Reduces muscle tension
- Smooths expression lines
- Gentle mechanism
Palmitoyl Tetrapeptide-7 reported benefits
- Anti-inflammatory (skin)
- Reduces IL-6
- Prevents collagen degradation
- Combats inflammaging
Related comparisons
Research and educational reference only. Not medical advice.